[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360096-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360096-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","liquid-biopsy-based-detection-of-acquired-met-resistance-enables-sequential-targeted-therapy-in-met-fusion-positive-nsclc","Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC","","Oncogenic MET alterations act as therapeutically actionable drivers in non-small cell lung cancer (NSCLC), with MET fusions occurring in roughly 0.1%–0.3% of cases. A 52-year-old woman with metastatic TTF1-positive lung adenocarcinoma carrying a KIF5B::MET fusion achieved a durable ~5-year response on third-line crizotinib. When tissue re-biopsies failed due to insufficient tumor cells, ctDNA revealed newly acquired MET kinase-domain resistance mutations (L1213V, Y1248C), suggesting retained sensitivity to type II inhibitors and guiding switch to cabozantinib.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/liquid-biopsy-based-detection-of-acquired-met-resistance-enables-sequential-targeted-therapy-in-met-fusion-positive-nsclc/360096/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/liquid-biopsy-based-detection-of-acquired-met-resistance-enables-sequential-targeted-therapy-in-met-fusion-positive-nsclc/360096.png","ImageObject",300,407,{"name":42,"@type":43},"Rizky","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was acquired MET resistance detected when tissue re-biopsy was not diagnostic?","Question",{"text":63,"@type":64},"Circulating tumor DNA (ctDNA) analysis identified two newly acquired on-target MET kinase domain resistance mutations (L1213V and Y1248C) alongside the known KIF5B::MET fusion.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What treatment sequence was used after progression on chemotherapy and immunotherapy?",{"text":68,"@type":64},"After initial progression, the patient received third-line crizotinib with a durable response, and upon suspected progression with ctDNA-confirmed resistance, treatment was switched to cabozantinib.",{"name":70,"@type":61,"acceptedAnswer":71},"Why was switching from a type I MET inhibitor to cabozantinib clinically relevant?",{"text":72,"@type":64},"Institutional molecular tumor board review considered the new MET kinase alterations mediators of resistance to type I MET inhibitors, with available data indicating preserved sensitivity to type II inhibitors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360096,1791069413,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","The Oncologist, 2026, 31, oyag151  \n[https://doi.org/10.1093/oncolo/oyag151](https://doi.org/10.1093/oncolo/oyag151)  \n[Published: April 21](Published: April 21), 2026  \nPrecision Medicine Clinic: Molecular Tumor Board  \nLiquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC  \nStanislav Rosnev1,2, , Katharina Klein1,2, Lukas Heukamp3, Julian Lenk4, Maria Joosten5, Markus M€obs5, , Tobias Grob5, Manuela Benary2,6, Loredana Vecchione1,2,7, Claus-Eric Ott8, , Dominik P. Modest1,2,7, Maren Kn€odler2, Ulrich Keller1,7,9, 10, , Nikolaj Frost11, , Ulrich Keilholz2,7, Philipp Kiewe†, 12, Damian T. Rieke*,†,1,2,7,   \n1 Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charit – Universit€atsmedizin Berlin, corporate member of Freie Universit€at Berlin and Humboldt-Universit€at zu Berlin, Berlin 12203, Germany  \n2Comprehensive Cancer Center, Charit – Universit€atsmedizin Berlin, corporate member of Freie Universit€at Berlin and Humboldt-Universit€at zu Berlin, Berlin 10117, Germany  \n3 Institute for Hematopathology Hamburg, Hamburg 22547, Germany  \n4 Department of Radiology, Charit – Universit€atsmedizin Berlin, corporate member of Freie Universit€at Berlin and Humboldt-Universit€at zu Berlin, Berlin 12203, Germany  \n5 Institute of Pathology, Charit – Universit€atsmedizin Berlin, corporate member of Freie Universit€at Berlin and Humboldt-Universit€at zu Berlin, Berlin 10117, Germany  \n6Core Unit Bioinformatics, Berlin Institute of Health at Charit – Universit€atsmedizin Berlin, Berlin 10117, Germany  \n7German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charit - Universit€atsmedizin Berlin, Berlin 10117, Germany 8 Institute for Medical and Human Genetics, Campus Virchow-Klinikum, Charit – Universit€atsmedizin Berlin, corporate member of Freie Universit€at Berlin and Humboldt-Universit€at zu Berlin, Berlin 13353, Germany  \n9 Max-Delbr€uck-Center for Molecular Medicine, Berlin 13125, Germany  \n10Cluster of Excellence ImmunoPreCept, Charit – Universit€atsmedizin Berlin, corporate member of Freie Universit€at Berlin and Humboldt-Universit€at zu Berlin, Berlin 10117, Germany  \n11 Department of Infectious Diseases and Pulmonary Medicine, Charit – Universit€atsmedizin Berlin, corporate member of Freie Universit€at Berlin and Humboldt-Universit€at zu Berlin, Berlin 13353, Germany  \n12Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin 14195, Germany † P. Kiewe and D.T. Rieke contributed equally.  \n*Corresponding author: Damian T. Rieke, Comprehensive Cancer Center, Charit - Universit€atsmedizin Berlin, Charitplatz 1, 10117 Berlin ([damian.rieke@charite.de](damian.rieke@charite.de)) .  \nAbstract  \nOncogenic alterations in MET represent therapeutically actionable driver alterations in non-small cell lung cancers (NSCLC). Among these, MET fusions are rare, occurring in approximately 0.1%-0.3% of NSCLC. We report the case of a 52-year-old woman with metastatic, TTF1-positive lung adenocarcinoma harboring a KIF5B::MET fusion. After progression on chemotherapy and immunotherapy, she achieved a durable response lasting nearly five years on third-line treatment with the type Ia MET inhibitor crizotinib. At the time of suspected disease progression, two tissue re-biopsies were non-diagnostic due of insufficient tumor cell content. Circulating tumor DNA (ctDNA) analysis identified two newly acquired ontarget resistance mutations within the MET kinase domain (L1213V and Y1248C) in addition to the known KIF5B::MET fusion. After re-evaluation by the institutional molecular tumor board, both alterations were considered mediators of resistance to type I MET inhibitors, with available data indicating preserved sensitivity to type II inhibitors. Based on these findings, the patient was switched to cabozantinib, a multikinase type II MET inhibitor, resulting in a radiographic disease stabilization accompanied by a marked decline","cbCaihg2wS0UBEuk","https://ap.wps.com/l/cbCaihg2wS0UBEuk","pdf",795266,"English","# Abstract\n# Key points\n# Introduction","[{\"question\":\"How was acquired MET resistance detected when tissue re-biopsy was not diagnostic?\",\"answer\":\"Circulating tumor DNA (ctDNA) analysis identified two newly acquired on-target MET kinase domain resistance mutations (L1213V and Y1248C) alongside the known KIF5B::MET fusion.\"},{\"question\":\"What treatment sequence was used after progression on chemotherapy and immunotherapy?\",\"answer\":\"After initial progression, the patient received third-line crizotinib with a durable response, and upon suspected progression with ctDNA-confirmed resistance, treatment was switched to cabozantinib.\"},{\"question\":\"Why was switching from a type I MET inhibitor to cabozantinib clinically relevant?\",\"answer\":\"Institutional molecular tumor board review considered the new MET kinase alterations mediators of resistance to type I MET inhibitors, with available data indicating preserved sensitivity to type II inhibitors.\"}]","Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC | PDF",1790138738,15,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01180bcf4fb9a22e871d0dcd5fd5d0e5.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24d02baffb4a20f88e42fe135c311483.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8176429eab4e934d5c36cca290688ec.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44a6803d4896cc4a32520d8945c66bc2.webp",980,1287]